Compare BioNano Genomics Inc (BNGO) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Iron Mountain Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Iron Mountain Inc trades at $123.59 (market cap $36.44B). The key difference: Iron Mountain Inc is far larger — about 2667.6× BioNano Genomics Inc's market cap, and Iron Mountain Inc pays a 2.82% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | IRM | |
|---|---|---|
Market Cap | $13.66M | $36.44B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $133.06 |
52-Week Low | $1.06 | $78.86 |
Enterprise Value | $16.26M | $55.85B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Iron Mountain (IRM) trades at $124.67, up 2.56% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $6.90B in 2025, though net margins compressed to 2.09%. The stock is supported by a 65% analyst buy rating and a $141.50 consensus target, with institutional interest highlighted by recent purchases. Key risks include high debt levels, with a debt-to-asset ratio of 79.04% in 2025.
Outlook remains mixed; robust data center growth and dividend yield near 2.8% offer upside, but elevated valuation (P/E 86.8) and persistent negative shareholder equity warrant caution. Earnings momentum from Q2 2026 beat provides near-term support, yet debt servicing and competitive pressures pose headwinds for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
